

Molecular imaging of T cell co-regulator factor B7-H3 with ⁸⁹Zr-DS-5573a

Ingrid Julienne Georgette Burvenich^{1,2*}, Sagun Parakh^{1,2,3*}, Fook-Thean Lee¹, Nancy Guo¹, Zhanqi Liu^{1,2}, Hui Kong Gan^{1,2,3,4}, Angela Rigopoulos^{1,2}, Graeme Joseph O'Keefe^{4,5}, Sylvia Jie Gong^{5,6}, Yit Wooi Goh¹, Henri Tochon-Danguy⁵, Fiona Elizabeth Scott^{1,2}, Masakatsu Kotsuma⁷, Kenji Hirotsu⁸, Giorgio Senaldi⁹ and Andrew M. Scott^{1,2,3,4,5}

¹Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia

²School of Cancer Medicine, La Trobe University, Melbourne, Australia

³Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia

⁴Department of Medicine, University of Melbourne, Melbourne, Australia

⁵Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia

⁶School of Engineering and Mathematical Sciences, La Trobe University

⁷Quantitative Clinical Pharmacology & Translational Sciences, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA

⁸Biologics & Immuno-Oncology Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo, Japan

⁹Department of Translational Medicine and Clinical Pharmacology, Daiichi-Sankyo Pharma Development, Edison, NJ, USA

* - authors contributed equally

Corresponding Author: Professor Andrew M. Scott, Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Level 5, ONJ Cancer Centre, 145 Studley Road, Heidelberg, Victoria 3084, Australia; Phone: 61-39496-5876; Fax: 61-39496-5334; E-mail: andrew.scott@onjcri.org.au

INDEX

Supplementary Figures




Figure S1 – Quality control of chelation and radiolabeling of ^{89}Zr -DS-5573a. SDS-PAGE analysis of native DS-5573a and Df-Bz-NCS-DS-5573a under non-reduced (A) and reduced conditions (B). The Df-Bz-NCS-DS-5573a was prepared without loss of structural integrity. Superdex 200 HR 10/30 Column Size Exclusion Chromatography (SEC) Analysis of ^{89}Zr -Df-Bz-NCS-DS-5573a integrity during incubation for 7 days in human serum at 37°C. The radiochromatograms (red) show one single peak at day 0 (C), day 3 (D) and day 7 (E). The UV chromatograms (black) show two peaks representing thyroglobulin (700 kDa, fraction 20) and human serum albumin (66 kDa, fraction 22).




Figure S2 – Influence of spleen size in different mouse strains on measured radioactivity concentration of ^{89}Zr -DS-5573a in the spleen. (A) Average weight of spleen from SCID mice versus BALB/c *nu/nu* mice ($n = 30$). **(B-C)** Spleen sizes measured in SCID mice ($n = 6$) and BALB/c *nu/nu* mice ($n = 5$) used for biodistribution study on day 3 post injection **(B)** and day 7 post injection **(C)**. **(D-E)** Radioactivity measured in the spleen at day 3 post injection in BALB/c *nu/nu* mice versus SCID mice presented as percentage injected dose **(D)** and percentage injected dose per gram tissue **(E)**. **(F-G)** Radioactivity measured in the spleen at day 7 post injection in BALB/c *nu/nu* mice versus SCID mice presented as percentage injected dose **(F)** and percentage injected dose per gram tissue **(G)**.




Figure S4 – Mice used to generate Figure 6E demonstrating the presence of a blood crust in the PBS-treated mouse injected with ^{89}Zr - Df-Bz-NCS-DS-5573 at a total dose of 3 mg/kg.